Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

Ligand Pharmaceuticals Target Price

Analysts' average 12-month price target for Ligand Pharmaceuticals is $340.

Get informed when a big investor buys or sells

+ Follow

Share Price

$301.52

Average Target Price

$338.50

12.3% upside

6 analysts in the last 4 months

High: $358 | Low: $326

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-14	Leerink Partners	$330	9.4% upside
2026-08-06	H.C. WainwrightJoseph Pantginis	$358	18.7% upside
2026-08-03	OppenheimerLeland Gershell	$326	8.1% upside
2026-07-20	Craig-HallumMatt Hewitt	$345	14.4% upside
2026-07-15	RBC Capital	$340	12.8% upside
2026-07-08	Stifel NicolausAnnabel Samimy	$332	10.1% upside
2026-04-30	H.C. WainwrightJoseph Pantginis	$289	4.2% downside
2026-04-28	RBC Capital	$252	16.4% downside
2026-04-27	Stifel Nicolaus	$255	15.4% downside
2026-04-14	H.C. WainwrightJoseph Pantginis	$243	19.4% downside
2026-02-24	H.C. WainwrightJoseph Pantginis	$239	20.7% downside
2025-12-10	Stifel Nicolaus	$230	23.7% downside
2025-12-10	OppenheimerTrevor Allred	$275	8.8% downside
2025-11-06	Stifel NicolausAnnabel Samimy	$220	27% downside
2025-11-06	H.C. Wainwright	$231	23.4% downside
2025-11-03	OppenheimerLeland Gershell	$250	17.1% downside
2025-09-03	OppenheimerLeland Gershell	$190	37% downside
2025-08-28	H.C. Wainwright	$206	31.7% downside
2025-02-28	UBS	$155	48.6% downside
2024-10-21	H.C. WainwrightJoseph Pantginis	$157	47.9% downside
2024-10-02	OppenheimerLeland Gershell	$135	55.2% downside
2024-07-30	RBC CapitalDouglas Miehm	$130	56.9% downside
2024-07-09	Craig-HallumMatt Hewitt	$140	53.6% downside
2024-06-28	H.C. WainwrightJoseph Pantginis	$144	52.2% downside
2022-12-23	Roth Capital	$90	70.2% downside

Ligand Pharmaceuticals (LGND) FAQ

As of the most recent data, LGND shows a target price of $340. Scroll down for historical charts and peer comparison views.

If Ligand Pharmaceuticals moved to the average analyst target of $340, shares would be roughly 12.3% higher than $301.52. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Ligand Pharmaceuticals's earnings trajectory.

Besides this target price page, Stockcircle has Ligand Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $340) with ownership activity and broader fundamentals.

Ligand Pharmaceuticals's target price is $340; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.